## TD1092

®

MedChemExpress

Cat. No.:	HY-151966
Molecular Formula:	C <sub>55</sub> H <sub>70</sub> N <sub>8</sub> O <sub>9</sub>
Molecular Weight:	987.19
Target:	IAP; PROTACs; Caspase
Pathway:	Apoptosis; PROTAC
Storage:	<b>4°C, protect from light</b> * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

BIOLOGICAL AC	ΓΙVITY					
Description	TD1092 is a pan-IAP degrader, degrades cIAP1, cIAP2, and XIAP. TD1092 activates Caspase 3/7, and promotes cancer cells apoptosis via IAP degradation. TD1092 inhibits TNFα mediated NF-κB pathway and reduces the phosphorylation of IKK, IkB α, p65, and p38. TD1092 can act as PROTAC, and is used for cancer research <sup>[1]</sup> .					
IC <sub>50</sub> & Target	cIAP1	cIAP2	XIAP	Caspase 3		
	Caspase-7					
In Vitro	TD1092 (0.01, 0.1 and 1 μ TD1092 (1 μM; 48 h and TD1092 (0.1 μM; 24 h) in TD1092 (1 μM; 6 h) inhib degradation <sup>[1]</sup> . TD1092 (1 μM; 72 h) inhi	TD1092 (1 $\mu$ M; 72 h) inhibits MCF-7 cells growth with an IG <sub>50</sub> value of 0.395 $\mu$ M <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				
	Cell Line:	MCF-7 cells				
	Concentration:	(1) 0, 0.1, 1, 10 μM or 0.1 μM (2) 0.1 μM, with or without 100 ng/mL TNFα				
	Incubation Time:	18 hours or 0.5, 1, 2, 4, 6 hours for (1) and 4 hours for (2)				
	Result:	Dose- and time-dependently decreases the protein level of cIAP1, cIAP2, and XIAP. Inhibited the phosphorylation of IKK, IkBα, p65, and p38 mediated by TNFα. Counterbalanced the effect of TNFα on the levels of E-cadherin (CDH1; an epithelial marker) and vimentin (VIM; a mesenchymal marker).				
	Cell Migration Assay <sup>[1]</sup>	Cell Migration Assay <sup>[1]</sup>				
	Cell Line:	MDA-MB-231 and MDA-MB-157 cells				

Concentration:	0.1 μM; with or without 100 ng/mL TNFα
Incubation Time:	24 hours
Result:	Inhibited TNFα-induced (100 ng/mL) migration and invasion against two triple-negative breast cancer (TNBC; MDA-MB-231 and MDA-MB-157) cell lines.

## REFERENCES

[1]. Park S, et al. Discovery of pan-IAP degraders via a CRBN recruiting mechanism. Eur J Med Chem. 2023 Jan 5;245(Pt 2):114910.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA